Zolmitriptan Tablets

Zolmitriptan is a prescription medicine used to treat migraine attacks once they've started. It belongs to the triptan family of medicines, the same class as sumatriptan, rizatriptan, almotriptan, and the others. In the UK it's available under the brand name Zomig (made by Grunenthal), as Zomig Rapimelt (the orodispersible wafer form), as Zomig nasal spray, and as generic zolmitriptan tablets. The standard tablets come in two strengths, 2.5 mg and 5 mg, and they're swallowed whole with water like any conventional tablet. Zolmitriptan is used for acute treatment of migraine with or without aura, and unlike triptans that come only as oral forms, the availability of a Rapimelt and nasal spray version makes it a flexible choice when different attack patterns call for different approaches.

Most triptans treat migraines the same way at receptor level, but they differ in practical details that shape who they suit best. Compared with sumatriptan, zolmitriptan has higher oral bioavailability (around 40 per cent versus 14 per cent for sumatriptan tablets), which means smaller doses do similar work. Zolmitriptan also penetrates into the brain slightly more readily, which some prescribers think makes it useful for migraines with prominent cognitive symptoms (brain fog, slowed thinking, confusion), although this point is partly empirical and partly theoretical. Compared with rizatriptan, zolmitriptan has a similar onset and bioavailability but doesn't have rizatriptan's specific dose-reducing interaction with propranolol. Compared with almotriptan, zolmitriptan is slightly less well tolerated (a few more triptan sensations, occasionally a bit more drowsiness) but available in more formats. One distinctive pharmacological feature is that zolmitriptan is converted in the body into an active metabolite that itself acts on triptan receptors, which gives the medicine a somewhat sustained effect.

Zolmitriptan is available in three different formats in the UK, which gives unusual flexibility for a single triptan. Standard tablets (2.5 mg and 5 mg) are swallowed with water and work like any conventional oral medicine. Zomig Rapimelt is an orodispersible wafer in the same strengths that dissolves on the tongue without water, useful when nausea makes swallowing tablets unpleasant or when water isn't available. Zomig nasal spray (5 mg) gives a faster onset (around 15 minutes) than either oral form and is useful when migraines come on quickly or when vomiting makes oral absorption unreliable. For most patients with typical migraine attacks, the standard tablet is fine and is the cheapest of the three formats. The Rapimelt suits people who get early nausea or who prefer the convenience of a wafer. The nasal spray is the option for fast-onset attacks where minutes matter. Some patients are prescribed two formats for different scenarios.

Migraine isn't a regular headache. During an attack, blood vessels in the head dilate, and a set of nerves around those vessels (the trigeminal nerves) release inflammatory chemicals that cause throbbing pain, nausea, sensitivity to light and sound, and the other classic migraine symptoms. Zolmitriptan works on receptors called 5-HT1B and 5-HT1D, which sit on those dilated vessels and on the nerve endings around them. Activating 5-HT1B receptors causes the dilated vessels to constrict back to their normal size. Activating 5-HT1D receptors stops the trigeminal nerves releasing the inflammatory chemicals that drive the pain. The result is that the migraine attack is interrupted at its source rather than just having the pain dulled. Because zolmitriptan crosses the blood-brain barrier slightly more readily than sumatriptan, it may also act on receptors within the brain itself that contribute to migraine, though this is an evolving area of understanding.

As early as possible after the headache phase begins. This is one of the most consistent findings in migraine research: triptans work much better when taken at the first sign of head pain than once a migraine is fully established. Many people with regular migraines learn to recognise the earliest signals: a slight visual disturbance, a dull ache behind one eye, a strange stiffness in the neck, or a sense that "something's coming". Acting at that point can often abort the attack entirely. Waiting until you're vomiting and lying down in a dark room reduces the chance of a good response significantly. If you have an aura before your headache, the usual advice is to wait until the headache itself starts before taking zolmitriptan, because the aura phase doesn't respond to triptans and you don't want to use up a dose too early.

Most prescribers start with 2.5 mg as the initial dose, because side effects are dose-related and many patients respond well to the lower strength. If 2.5 mg gives partial relief or doesn't quite stop an attack after one or two trial attempts, the dose can be increased to 5 mg for future attacks. A small number of patients need 5 mg from the start, and that's a decision made with the prescriber. If a migraine comes back within 24 hours after an initial response, a second dose (of whichever strength is being used) can be taken at least 2 hours after the first, up to a maximum of 10 mg in 24 hours. As with other triptans, taking a second dose for the same attack isn't recommended if the first dose has had no effect at all. Doses are reduced in significant liver or kidney impairment.

Zolmitriptan tablets typically start to take effect within 30 to 45 minutes of being swallowed, with peak effect at around 2 hours. About 65 to 70 per cent of people get meaningful pain relief within 2 hours of taking the standard dose, and around 35 to 45 per cent are completely pain-free at 2 hours. Earlier dosing in the attack pushes those numbers up; waiting until the attack is fully established pushes them down. Zolmitriptan tablets are slightly slower in onset than rizatriptan tablets and faster than naratriptan or frovatriptan, but the difference is rarely dramatic from the patient's perspective. If speed of onset matters more than the format, the Zomig Rapimelt (similar onset to standard tablets, since dissolving in the mouth doesn't change where the medicine is absorbed) or the Zomig nasal spray (around 15 minutes onset) may be worth discussing with a prescriber.

The general rule is to avoid taking a second dose for the same attack if the first dose has had no effect at all. If it partially worked or worked and then wore off, a second dose can help, but if it did nothing at the first attempt, more of the same is unlikely to help. Options at that point include adding a painkiller such as ibuprofen or naproxen, an anti-sickness medicine like metoclopramide (which also helps the gut absorb other medicines better), or waiting the attack out in a dark, quiet room with hydration. For future attacks, it's worth a conversation with your prescriber about whether another triptan might work better. Triptans are not interchangeable; many people who don't respond to one will respond to another, and it's reasonable to try several before concluding the class doesn't work for you. Sumatriptan, rizatriptan, almotriptan, naratriptan, eletriptan, and frovatriptan are the main alternatives in the UK, each with slightly different speed, duration, and tolerability profiles.

Most people tolerate zolmitriptan well. The "triptan sensations" common to this class of medicine include tingling, a feeling of warmth or coolness, mild flushing, and a sense of pressure or tightness that can be felt in the chest, throat, neck, jaw, or limbs. The chest tightness in particular tends to alarm people the first time they experience it, because the natural assumption is that it's something cardiac. In healthy people without heart disease this sensation isn't dangerous and reflects the medicine's action on blood vessels and smooth muscle. It usually settles within 30 minutes to an hour. That said, real cardiac chest pain can occur in someone with undiagnosed heart disease who takes a triptan, so the distinction matters. If the chest sensation is severe, prolonged, crushing, associated with breathlessness, or radiating down the arm, that needs urgent assessment rather than being assumed to be a "triptan sensation". Other common side effects of zolmitriptan include drowsiness (slightly more than with almotriptan, because of the better CNS penetration), dizziness, fatigue, dry mouth, mild taste changes, and nausea.

A few interactions matter, and one set is somewhat distinctive to zolmitriptan. Like all triptans, it should not be taken with monoamine oxidase inhibitor antidepressants (MAOIs) or within two weeks of stopping one, because of the risk of dangerous blood pressure rises and serotonin syndrome. It shouldn't be combined with another triptan or with ergotamine-type migraine medicines on the same day, because the vasoconstriction effects can add up. SSRIs and SNRIs carry a small theoretical risk of serotonin syndrome, though this is rare in practice. The distinctive interactions for zolmitriptan involve medicines that inhibit the liver enzyme CYP1A2, which is the main enzyme that breaks down zolmitriptan. The most relevant in everyday practice are cimetidine (an older stomach acid medicine, now less commonly used), fluvoxamine (an SSRI antidepressant), and ciprofloxacin (a commonly prescribed antibiotic). Each of these can significantly raise zolmitriptan blood levels and lead to a recommendation that the dose be halved (so a 2.5 mg starting dose rather than the usual 5 mg, and a 5 mg daily maximum rather than 10 mg). Hormonal contraceptives also mildly raise zolmitriptan levels but rarely require a dose change. Always tell prescribers what else you're taking so any interactions can be managed properly.

Yes, in most cases. Zolmitriptan causes blood vessel constriction including in the coronary arteries that supply the heart muscle. In someone with healthy arteries this is harmless and transient, but in someone whose coronary arteries are already narrowed by atherosclerosis, even a small additional constriction can reduce blood flow to the heart enough to cause angina or, in rare cases, a heart attack. Zolmitriptan is contraindicated in established ischaemic heart disease, previous heart attack, coronary artery vasospasm (Prinzmetal's angina), uncontrolled high blood pressure, previous stroke, and peripheral vascular disease. It's also specifically contraindicated in Wolff-Parkinson-White syndrome and other conditions involving accessory cardiac conduction pathways, because of the small risk of triggering arrhythmias. Zolmitriptan is used with caution in people who don't have known heart disease but who carry significant cardiovascular risk factors (men over 40, postmenopausal women, smokers, diabetes, raised cholesterol, family history of premature heart disease). In those situations a cardiovascular assessment before starting any triptan is often recommended.

The safety data for zolmitriptan in pregnancy is more limited than for sumatriptan, which has a longer track record and a larger accumulated registry of pregnancy outcomes. What evidence exists doesn't show clear harm, but most clinicians prefer sumatriptan in pregnancy where a triptan is needed, because of the larger safety database. If you're pregnant and considering zolmitriptan, the conversation is worth having with your GP rather than self-managing. In breastfeeding, zolmitriptan passes into breast milk in small amounts, and the standard advice is to avoid breastfeeding for 24 hours after a dose, although more recent guidance takes a more relaxed view in some cases. Many women express and discard breast milk during that window to maintain supply.

This is one of the most important things to understand about triptans, because the danger isn't using them, it's using them too often. Medication overuse headache (MOH) is a surprisingly common problem in which the body's response to frequent triptan use becomes paradoxical: the medicines that were helping start producing rebound headaches, which then prompt more medicine use, in a cycle that can become entrenched. The current threshold is taking a triptan on more than 10 days a month, on average, for three or more months. Above that level, the risk of MOH rises significantly. If you find yourself reaching for zolmitriptan 10 or more days a month, that's a strong signal that the conversation needs to shift from acute treatment to preventive treatment, a different category of medicine designed to reduce how often migraines happen in the first place. Treatment of medication overuse headache involves stopping the overused medicine for a period to allow the headache pattern to reset, often with specialist guidance, and the headache pattern usually settles into a better baseline once that's been done.

No, zolmitriptan is an acute treatment: it interrupts a migraine once it's started. It doesn't change how often migraines happen, how severe they are when they do, or any of the underlying drivers of the condition. Prevention is a separate category of treatment worth discussing with a clinician if your migraines are frequent (more than four a month is a common threshold), severely disabling, or not well controlled with acute treatment. Preventive options include beta-blockers (propranolol), topiramate, amitriptyline, candesartan, and the newer injected CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab). Botulinum toxin injections are also licensed for chronic migraine prevention. Beyond the prevention question, several features call for prompt medical review: a first-ever severe headache, particularly one that comes on suddenly or feels different from anything you've had before (which can be a warning of meningitis or subarachnoid haemorrhage and should be treated as an emergency); migraine lasting more than 72 hours without responding to treatment ("status migrainosus"); new neurological symptoms during a migraine that don't fit your usual aura pattern; headaches that wake you from sleep, consistently get worse over weeks, or come with weight loss, fever, or other systemic symptoms. A clinical review is also worth having if your migraines are happening often, if zolmitriptan isn't enough, if you're using it on more than 10 days a month, or if you've never had a formal migraine diagnosis. Modern migraine care has changed considerably in the last decade with the arrival of CGRP-targeting treatments, and many people who've been managing on triptans alone for years find that a proper review opens up better options.